drugset / Trial / NCT05669001
A Study of TCD601 in de Novo Renal Transplant Recipients
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.
Timeline
- Start
- 2023-12-28
- Primary completion
- 2026-04-10
- Completion
- 2026-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ATG | Unknown | — | — |
| Subject | Belatacept | Protein / enzyme biologic | — | — |
| Subject | Siplizumab | Monoclonal antibody | — | — |
| Comparator | TAC | Unknown | — | — |
| Background | MPA | Unknown | — | — |
| Background | Prednisone | Other / unclassified | — | — |
Indications
No indication recorded.